131 related articles for article (PubMed ID: 9267787)
1. Predicting pelvic lymph node involvement in patients with localized prostate cancer.
Ekman P
Eur Urol; 1997; 32 Suppl 3():60-4. PubMed ID: 9267787
[TBL] [Abstract][Full Text] [Related]
2. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
Stone NN; Stock RG
Mt Sinai J Med; 1999 Jan; 66(1):26-30. PubMed ID: 9989102
[TBL] [Abstract][Full Text] [Related]
3. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
[TBL] [Abstract][Full Text] [Related]
4. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
5. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
[TBL] [Abstract][Full Text] [Related]
6. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
Weckermann D; Dorn R; Trefz M; Wagner T; Wawroschek F; Harzmann R
J Urol; 2007 Mar; 177(3):916-20. PubMed ID: 17296375
[TBL] [Abstract][Full Text] [Related]
8. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
9. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
Heidenreich A; Varga Z; Von Knobloch R
J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
[TBL] [Abstract][Full Text] [Related]
10. [Staging pelvic lymphadenectomy for carcinoma of the prostate: review of 23 cases].
Arai Y; Taniguchi T; Kaku S; Kihara Y; Okada K; Kawamura J
Hinyokika Kiyo; 1986 Mar; 32(3):401-6. PubMed ID: 3728242
[TBL] [Abstract][Full Text] [Related]
11. The value of prostate-specific antigen levels in pelvic lymph nodes for diagnosing metastatic spread of prostate cancer.
Shoskes DA; Trachtenberg J
Can J Surg; 1993 Feb; 36(1):33-6. PubMed ID: 7680271
[TBL] [Abstract][Full Text] [Related]
12. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen for prostate cancer staging in a population-based register.
Sandblom G; Holmberg L; Damber JE; Hugosson J; Johansson JE; Lundgren R; Mattsson E; Nilsson J; Varenhorst E
Scand J Urol Nephrol; 2002; 36(2):99-105. PubMed ID: 12028682
[TBL] [Abstract][Full Text] [Related]
14. Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: results of the first 100 cases.
Bastide C; Brenot-Rossi I; Garcia S; Rossi D
Eur J Surg Oncol; 2009 Jul; 35(7):751-6. PubMed ID: 18538526
[TBL] [Abstract][Full Text] [Related]
15. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer.
Wyler SF; Sulser T; Seifert HH; Ruszat R; Forster TH; Gasser TC; Bachmann A
Urology; 2006 Oct; 68(4):883-7. PubMed ID: 17070376
[TBL] [Abstract][Full Text] [Related]
16. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
Steven K; Poulsen AL
J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
[TBL] [Abstract][Full Text] [Related]
17. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
[TBL] [Abstract][Full Text] [Related]
18. Lymph node assessment and lymphadenectomy in prostate cancer.
Ordon M; Nam RK
J Surg Oncol; 2009 Mar; 99(4):215-24. PubMed ID: 19170044
[TBL] [Abstract][Full Text] [Related]
19. The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy?
Gingrich JR; Paulson DF
Surg Oncol Clin N Am; 1995 Apr; 4(2):335-44. PubMed ID: 7540939
[TBL] [Abstract][Full Text] [Related]
20. Regional lymph node staging in prostate cancer: prognostic and therapeutic implications.
Burkhard FC; Studer UE
Surg Oncol; 2009 Sep; 18(3):213-8. PubMed ID: 19269808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
